文献速递泌尿男性生殖肿瘤支持与姑息治疗

前列腺癌治疗后的长期不良反应与并发症

Long-Term Adverse Effects and Complications After Prostate Cancer Treatment.
PubMed 文献 · JAMA Oncol · 2024-11-07

这项队列研究将两项前列腺癌预防临床试验数据与Medicare理赔记录链接,比较接受前列腺切除术或放疗的前列腺癌患者与未治疗对照的10种治疗相关并发症。中位12年随访显示,手术和放疗均与泌尿或性并发症风险升高相关,放疗还与膀胱癌及放射性膀胱炎、放射性直肠炎风险显著升高相关。

要点

  • 前列腺切除术后12年泌尿或性并发症风险为未治疗者的7.23倍(95%CI 5.96-8.78)。
  • 放疗后12年泌尿或性并发症风险为未治疗者的2.76倍(95%CI 2.26-3.37)。
  • 放疗者放射性膀胱炎HR 131.47、放射性直肠炎HR 87.91,均P<.001。

核心结论

  • 即使考虑年龄相关症状和疾病,前列腺癌治疗仍与治疗后12年内更高的并发症发生率相关。
  • 鉴于前列腺癌治疗对多数患者获益不确定,这些发现强调在前列腺癌筛查和治疗前进行患者咨询的重要性,并为探索癌症预防机会提供了依据。

研究设计与样本

  • 队列研究,将前列腺癌预防试验(Prostate Cancer Prevention Trial)和硒与维生素E癌症预防试验(Selenium and Vitamin-E Cancer Prevention Trial)两项大型前列腺癌预防临床试验的数据与Medicare理赔记录链接。
  • 分析纳入接受前列腺切除术或放疗的前列腺癌患者,与未治疗对照组比较;采用多变量Cox回归,以时变协变量表示前列腺癌治疗的发生,校正年龄、种族和风险起始年份,并按研究和干预臂分层。
  • 研究样本共29196名参与者,风险起始时平均(SD)年龄68.7(4.8)岁;其中3946名患前列腺癌,655名接受前列腺切除术,1056名接受放疗。
  • 数据分析时间为2022年9月21日至2024年3月18日。
  • 暴露为前列腺癌诊断后发生的前列腺切除术和放疗,通过试验数据或Medicare理赔记录识别。

主要发现

  • 与未治疗参与者相比,前列腺切除术者12年泌尿或性并发症风险为7.23倍(95%CI 5.96-8.78;P<.001),放疗者为2.76倍(95%CI 2.26-3.37;P<.001)。
  • 放疗参与者膀胱癌风险约为未治疗者的3倍(HR 2.78;95%CI 1.92-4.02;P<.001)。
  • 放疗参与者放射性膀胱炎风险升高约100倍(HR 131.47;95%CI 52.48-329.35;P<.001),放射性直肠炎风险也升高约100倍(HR 87.91;95%CI 48.12-160.61;P<.001)。
  • 10种治疗相关并发症中任一种的发生率每1000人年分别为:前列腺切除术124.26、放疗62.15、未治疗23.61。

关键数值与推荐

  • 主要结局为从Medicare理赔数据中识别的10种潜在前列腺癌治疗相关并发症。
  • 前列腺切除术者12年泌尿或性并发症风险为未治疗者的7.23倍(95%CI 5.96-8.78;P<.001)。
  • 放疗者12年泌尿或性并发症风险为未治疗者的2.76倍(95%CI 2.26-3.37;P<.001)。
  • 放疗者膀胱癌HR 2.78(95%CI 1.92-4.02;P<.001)。
  • 放疗者放射性膀胱炎HR 131.47(95%CI 52.48-329.35;P<.001),放射性直肠炎HR 87.91(95%CI 48.12-160.61;P<.001)。

临床怎么用

  • 作者认为,这些发现强调在前列腺癌筛查和治疗前进行患者咨询的重要性。
  • 作者认为,这些发现为探索癌症预防机会提供了依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Due to the often indolent nature of prostate cancer (PCA), treatment decisions must weigh the risks and benefits of cancer control with those of treatment-associated morbidities. OBJECTIVE: To characterize long-term treatment-related adverse effects and complications in patients treated for PCA compared to a general population of older males. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used a novel approach linking data from 2 large PCA prevention clinical trials (the Prostate Cancer Prevention Trial and the Selenium and Vitamin-E Cancer Prevention Trial) with Medicare claims records. This analysis included patients with PCA who had been treated with prostatectomy or radiotherapy compared with an untreated control group. Multivariable Cox regression was used, with a time-varying covariate for the occurrence of PCA treatment, adjusted for age, race, and year of time-at-risk initiation, and stratified by study and intervention arm. Data analyses were performed from September 21, 2022, to March 18, 2024. EXPOSURE: Prostatectomy and radiotherapy occurring after a PCA diagnosis, identified from trial data or Medicare claims records. MAIN OUTCOMES AND MEASURES: Ten potential PCA treatment-related complications identified from Medicare claims data. RESULTS: The study sample comprised 29 196 participants (mean [SD] age at time-at-risk initiation, 68.7 [4.8] years). Of these, 3946 participants had PCA, among whom 655 were treated with prostatectomy and 1056 with radiotherapy. The 12-year hazard risk of urinary or sexual complications was 7.23 times greater for those with prostatectomy (95% CI, 5.96-8.78; P < .001) and 2.76 times greater for radiotherapy (95% CI, 2.26-3.37; P < .001) compared to untreated participants. Moreover, among participants treated with radiotherapy, there was a nearly 3-fold greater hazard risk of bladder cancer than in the untreated (hazard ratio [HR], 2.78; 95% CI, 1.92-4.02; P < .001), as well as an approximately 100-fold increased hazard risk of radiation-specific outcomes including radiation cystitis (HR, 131.47; 95% CI, 52.48-329.35; P < .001) and radiation proctitis (HR, 87.91; 95% CI, 48.12-160.61; P < .001). The incidence per 1000 person-years of any 1 of the 10 treatment-related complications was 124.26 for prostatectomy, 62.15 for radiotherapy, and 23.61 for untreated participants. CONCLUSIONS AND RELEVANCE: This cohort study found that, even after accounting for age-related symptoms and disease, PCA treatment was associated with higher rates of complications in the 12 years after treatment. Given the uncertain benefit of PCA treatment for most patients, these findings highlight the importance of patient counseling before PCA screening and treatment and provide a rationale for pursuing opportunities for cancer prevention.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Unger JM, Till C, Tangen CM, et al. Long-Term Adverse Effects and Complications After Prostate Cancer Treatment. JAMA Oncol. 2024. PMID: 39509091. doi:10.1001/jamaoncol.2024.4397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。